Kura Oncology, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
During the three months ended June 30, 2026, certain of our officers adopted, modified or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
| Trading Arrangement | ||||||
| Name and Position | Action | Date | Rule 10b5-1(1) | Non-Rule 10b5-1(2) | Total Shares to be Sold | Expiration Date |
|---|---|---|---|---|---|---|
| Teresa Bair, Chief Legal Officer | Termination(3) | May 20, 2026 | X | 218,021 shares, and ESPP net shares to be purchased | December 5, 2026 | |
| Teresa Bair, Chief Legal Officer | Adoption(3) | May 20, 2026 | X | 235,718 shares, and ESPP net shares to be purchased | May 31, 2027 | |
| Brian Powl, Chief Commercial Officer | Termination(4) | May 22, 2026 | X | 219,434 shares, options net shares unsold, RSUs net shares to be received, and ESPP net shares to be purchased | December 31, 2026 | |
| Brian Powl, Chief Commercial Officer | Adoption(4) | May 22, 2026 | X | 226,332 shares, options net shares unsold, RSUs net shares to be received, and ESPP net shares to be purchased | May 31, 2027 | |
| Kathleen Ford, Chief Operating Officer | Adoption | May 29, 2026 | X | 30,000 shares, options net shares unsold, PSUs and RSUs net shares to be received, and ESPP net shares to be purchased | May 31, 2027 | |
(1) Intended to satisfy the affirmative defense of Rule 10b5-1(c)
(2) Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
(3)Representsthe modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on September 4, 2025 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(4)Representsthe modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 18, 2025 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
In addition, our officers (as defined in Rule 16a-1(f) under the Exchange Act) have entered into sell-to-cover arrangements adopted pursuant to Rule 10b5-1 authorizing the pre-arranged sale of shares to satisfy our tax withholding obligations arising exclusively from the vesting of shares of restricted stock. The amount of shares to be sold to satisfy our tax withholding obligations under these arrangements is dependent on future events which cannot be known at this time, including the future trading price of our shares. The expiration date relating to these arrangements is dependent on future events which cannot be known at this time, including the final vesting date of the applicable shares of restricted stock and the officer’s termination of service.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.